ArticleOncology letters2026
Malignant mesothelioma of the tunica vaginalis testis: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to report a case of malignant mesothelioma of the tunica vaginalis testis (MMTVT) and to discuss clinicopathological features and therapeutic dilemmas to provide references for individualized management of similar cases. The case of a 57-year-old male patient with MMTVT, admitted in February 2025, was retrospectively analyzed. The patient presented with left scrotal pain and had a 30-year history of vasectomy. Scrotal ultrasound, testicular MRI and serum tumor marker analyses were performed, followed by local resection of the left tunica vaginalis tumor under spinal anesthesia. Diagnosis was confirmed using postoperative pathology and immunohistochemistry. After comprehensive counseling on recurrence and metastasis risks, the patient and their family declined radical orchiectomy and adjuvant chemotherapy, and close surveillance was instituted. Postoperative pathology confirmed biphasic MMTVT. Immunohistochemistry demonstrated positive mesothelial biomarkers: D2-40(+), calretinin (focal+) and cytokeratin 5/6 (focal weak+). Ki-67 was ~10%, with wild-type p53 expression. The tumor was completely excised with negative margins. No recurrence or metastasis was observed at the 12-month follow-up. This case, presenting with scrotal pain as initial presentation, further highlights the clinical heterogeneity of MMTVT. The remote vasectomy history, which is rarely documented, raises an etiological question for investigation. The biphasic subtype with low Ki-67 suggests that prognostic evaluation requires integrating histological subtype and molecular biomarkers. The 12-month recurrence-free survival time following isolated local excision provides preliminary evidence for organ-sparing management, although long-term outcomes require continued surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.